ArticleFrontiers in medicine2026
Adjuvant intravenous immunoglobulin in elderly sepsis: a randomized controlled study of mortality, organ function, and inflammation.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis carries high mortality in older people, and immunomodulatory adjuncts to standard therapy are needed. To evaluate the efficacy and safety of intravenous immunoglobulin (IVIG) as an adjunct to conventional treatment in elderly patients with sepsis. Methods: In this single-center, prospective, open-label study with blinded outcome assessment, 120 elderly patients (≥65 years) meeting Sepsis-3 criteria were randomized to receive IVIG (0.4 g/kg/day for 3 days) plus conventional therapy ( Results: Baseline characteristics were balanced. IVIG was associated with reduced 28-day mortality (18.3% vs. 31.7%; relative risk, 0.58; 95% CI, 0.31-0.97; Conclusion: Adjunctive IVIG therapy in elderly sepsis patients was associated with lower 28-day mortality, accelerated recovery of organ function, reduced systemic inflammation, and decreased ICU resource utilization, with a favorable safety profile. These findings provide a direct link between immunomodulation and improved clinical outcomes in geriatric intensive care, supporting further evaluation of IVIG in larger multicenter studies targeting this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.